[Skip to Content]
[Skip to Content Landing]
June 9, 2004

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events

JAMA. 2004;291(22):2701. doi:10.1001/jama.291.22.2701-a

To Editor: Dr Levine and colleagues1 found that the presence of antiphospholipid antibodies (aPL) among patients with ischemic stroke did not predict an increased risk for subsequent vascular occlusive events. Thus, the authors concluded that routine screening for aPL did not appear warranted for secondary prevention of stroke. These results appear discordant, however, with a previous study by the same authors, which found that presence of anticardiolipin antibodies (aCL) was associated with a higher risk of stroke.2

First Page Preview View Large
First page PDF preview
First page PDF preview